<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Struct Heart</journal-id><journal-id journal-id-type="iso-abbrev">Struct Heart</journal-id><journal-title-group><journal-title>Structural Heart</journal-title></journal-title-group><issn pub-type="ppub">2474-8706</issn><issn pub-type="epub">2474-8714</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11864126</article-id><article-id pub-id-type="pii">S2474-8706(24)00108-8</article-id><article-id pub-id-type="doi">10.1016/j.shj.2024.100353</article-id><article-id pub-id-type="publisher-id">100353</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Early Outcomes With Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement in Patients With Atrial Fibrillation</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Shekhar</surname><given-names>Shashank</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author" id="au2"><name><surname>Krishnaswamy</surname><given-names>Amar</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author" id="au3"><name><surname>Reed</surname><given-names>Grant</given-names></name><degrees>MD, MSc</degrees></contrib><contrib contrib-type="author" id="au4"><name><surname>Yun</surname><given-names>James</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author" id="au5"><name><surname>Puri</surname><given-names>Rishi</given-names></name><degrees>MD, PhD</degrees></contrib><contrib contrib-type="author" id="au6"><name><surname>Kapadia</surname><given-names>Samir</given-names></name><degrees>MD</degrees><email>kapadis@ccf.org</email><ext-link ext-link-type="uri" xlink:href="https://twitter.com/tavrkapadia">@tavrkapadia</ext-link><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1">Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Address correspondence to: Samir R. Kapadia, MD, FACC, FAHA, Chair, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, 9500 Euclid Avenue, J2-3, Cleveland, OH 44195. <email>kapadis@ccf.org</email><ext-link ext-link-type="uri" xlink:href="https://twitter.com/tavrkapadia">@tavrkapadia</ext-link></corresp></author-notes><pub-date pub-type="pmc-release"><day>02</day><month>9</month><year>2024</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>1</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>9</month><year>2024</year></pub-date><volume>9</volume><issue>1</issue><elocation-id>100353</elocation-id><history><date date-type="received"><day>6</day><month>3</month><year>2024</year></date><date date-type="rev-recd"><day>9</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>3</day><month>7</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 The Authors</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Background</title><p>Limited studies are available which aim to identify patient populations that would potentially benefit from the use of cerebral embolic protection devices (CPDs) during transcatheter aortic valve replacement (TAVR). We aimed to analyze the impact of CPD use during TAVR among patients with atrial fibrillation (AF).</p></sec><sec><title>Methods</title><p>Data on adult TAVR patients with a concomitant diagnosis of AF was obtained from the 2017-2020 National Readmissions Database. Stroke, major stroke, in-hospital mortality, and 30-day readmission rates were compared between the CPD and no-CPD cohorts in a propensity score matched analysis. Association of CPD use with adverse events was analyzed using multivariable logistic regression models.</p></sec><sec><title>Results</title><p>Of 100,928 eligible TAVR patients with AF, CPD was used in 6.9% of patients with a mean age of 80 years. CPD use was independently associated with lower overall stroke (1.7% vs. 2.2%; odds ratio [OR] 0.81 [95% CI 0.68-0.98]; <italic>p</italic> = 0.032), major stroke (1.2% vs. 1.8%; OR 0.69 [0.55-0.86]; <italic>p</italic> = 0.001), in-hospital mortality (0.9 vs. 1.5%; OR 0.56 [0.43-0.72]; <italic>p</italic> &#x0003c; 0.001), and lower 30-day readmission rates (12.7% vs. 14.7%; OR 0.87 [0.81-0.94]; <italic>p</italic> &#x0003c; 0.001). Reduction in adverse events with CPD was noted in high-volume but not in low-volume TAVR centers.</p></sec><sec><title>Conclusions</title><p>The present point towards clear benefits of CPD use among patients with AF undergoing TAVR. In anatomically eligible patients, the potential benefit of debris capture may be considered especially as younger and lower risk patients become eligible for TAVR. Data from future trials and registries are required to further corroborate our findings.</p></sec></abstract><abstract abstract-type="author-highlights" id="abs0015"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Stroke remains a formidable cause of morbidity, mortality, and resource utilization in transcatheter aortic valve replacement (TAVR) patients.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">Sentinel cerebral embolic protection device (CPD) is designed to capture and remove debris thereby reducing the risk of stroke.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">There is an interest in identifying patients who may benefit from the use of the CPD.</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">Patients with atrial fibrillation undergoing TAVR with CPD had lower overall stroke, and major stroke.</p></list-item><list-item id="u0030"><label>&#x02022;</label><p id="p0030">Thirty-day all cause readmissions were lower in patients with atrial fibrillation undergoing TAVR with CPD use.</p></list-item><list-item id="u0035"><label>&#x02022;</label><p id="p0035">Future studies from other registries and clinical trials are required to corroborate our findings and to identify candidates for CPD use.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Cerebral embolic protection</kwd><kwd>Mortality</kwd><kwd>Sentinel</kwd><kwd>Stroke</kwd><kwd>Transcatheter aortic valve replacement</kwd></kwd-group></article-meta><def-list><title>Abbreviations</title><def-item><term id="kwrd0040">AF</term><def><p>atrial fibrillation</p></def></def-item><def-item><term id="kwrd0050">AS</term><def><p>aortic stenosis</p></def></def-item><def-item><term id="kwrd0060">CPD</term><def><p>cerebral protection device</p></def></def-item><def-item><term id="kwrd0070">HCUP</term><def><p>Healthcare Cost and Utilization Project</p></def></def-item><def-item><term id="kwrd0080">ICD</term><def><p>International Classification of Diseases</p></def></def-item><def-item><term id="kwrd0090">NRD</term><def><p>Nationwide Readmissions Database</p></def></def-item><def-item><term id="kwrd0100">OR</term><def><p>odds ratio</p></def></def-item><def-item><term id="kwrd0110">RCT</term><def><p>randomized controlled trial</p></def></def-item><def-item><term id="kwrd0120">TAVR</term><def><p>transcatheter aortic valve replacement</p></def></def-item></def-list></front><body><sec id="sec1"><title>Introduction</title><p id="p0040">Stroke remains a devastating and feared complication of the revolutionary transcatheter aortic valve replacement (TAVR) procedure, affecting nearly 2% of TAVR patients.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Post-TAVR stroke is associated with increased mortality.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> In order to decrease the potential complication of stroke relating to the TAVR procedure, cerebral embolic protection devices (CPDs) have been developed.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref></p><p id="p0045">The SENTINEL CPD (Boston Scientific Corp, Boston, Massachusetts) was approved by the United States Food and Drug Administration for stroke prevention during TAVR<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> following results from the SENTINEL randomized controlled trial (RCT) which demonstrated the safety of the device in 363 high-risk patients with aortic stenosis (AS).<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> The recently published results of the PROTECTED TAVR RCT (Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement) further demonstrated the efficacy of the CPD device in reducing disabling stroke among 3000 TAVR patients across 50 global sites, at all surgical levels (0.5% in protected vs. 1.3% in unprotected, <italic>p</italic> = 0.02).<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> However, the RCT did not aim to identify patients with specific underlying comorbidities who would benefit from CPD use.</p><p id="p0050">Patients with atrial fibrillation (AF) are known to be at a high-risk for stroke, possibly due to cardioembolic events in the left atrial appendage.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> In an effort to identify candidates who may potentially benefit from CPD, we aimed to assess the outcomes of patients with AF who underwent TAVR with and without the use of CPD.</p></sec><sec id="sec2"><title>Methods</title><sec id="sec2.1"><title>Data Source</title><p id="p0055">The present study was conducted from data obtained from Nationwide Readmissions Database (NRD) (2017-2020) maintained by the Healthcare Cost and Utilization Project (HCUP) of the Agency for Healthcare Research and Quality in the United States.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> The data set is the largest publicly available database representing &#x0223c;52% of all US hospitalizations. Patients are tracked using verifiable linkage numbers during a calendar year, i.e., from January to the end of December. Patient characteristics, diagnoses, and procedures are coded in the database using the International Classification of Diseases (ICD) ninth and 10th Revision Clinical Modification and Procedure Coding System codes. Since the data are publicly available and contain deidentified information, approval from the institutional review board was not required for this study. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist was used when writing the present report.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref></p><sec id="sec2.1.1"><title>Study Design</title><p id="p0060"><xref rid="appsec1" ref-type="sec">Supplementary Table 1</xref> lists the ICD-10 Clinical Modification and Procedure Coding System codes used for the present study. Data on adult transfemoral TAVR recipients were extracted using verified ICD-10 codes (&#x02018;02RF37Z,&#x02019; &#x02018;02RF38Z,&#x02019; &#x02018;02RF3JZ,&#x02019; and &#x02018;02RF3KZ&#x02019;).<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Patients with concomitant surgery (surgical aortic valve replacement, coronary bypass surgery, or thoracic aorta surgery) were excluded, and only those with a diagnosis of AF were included in the analysis. Hospitals were categorized into metropolitan teaching hospitals vs others.</p></sec></sec><sec id="sec2.2"><title>Definitions and Outcomes</title><p id="p0065">The variable <italic>DISPUNIFORM</italic> provided by the HCUP contains information on the discharge disposition of patients and is coded from &#x02018;1 to 7&#x02019; and &#x02019;20,&#x02019; corresponding to routine home/self-care discharge, &#x02018;20&#x02019; representing death, and the rest representing discharge to another hospital/nursing facility (short-term hospital, skilled nursing facility, intermediate care facility, another type of facility, or home health care). This information was used to define &#x0201c;major stroke&#x0201d; in the present study as stroke which resulted in death or discharge to another hospital/nursing facility.</p><p id="p0070">The variable <italic>HOSP_NRD</italic> provided by the HCUP was used for the calculation of annual hospital procedural volumes. Hospitals were categorized into low-volume TAVR centers if the number of procedures performed was &#x02264;99 TAVR procedures in each year, and high-volume TAVR centers if the number of procedures performed was &#x02265;100 TAVR procedures.</p><p id="p0075">Overall stroke, major stroke, length of stay, routine discharges, in-hospital mortality, and 30-day readmission outcomes were compared between patients who underwent TAVR with and without the use of a CPD (&#x02018;X2A5312&#x02019;). The weight variable provided by the HCUP, <italic>DISCWT</italic>, was used in order to obtain national estimates.</p></sec><sec id="sec2.3"><title>Statistical Analysis</title><p id="p0080">We compared patient characteristics and outcomes between the CPD and no-CPD cohorts using Fisher exact text or chi-square test for categorical variables, and Mann-Whitney <italic>U</italic> test or Student <italic>t</italic> test continuous variables. To mitigate the risk of confounding and selection bias, a propensity score matching model was developed using logistic regression to derive 2 matched groups. The MatchIt program in R statistical software was used to perform a 1:2 nearest neighbor matching, using a caliper of 0.1. Details of the propensity matching appear in the <xref rid="appsec1" ref-type="sec">Supplementary Materials</xref> (<xref rid="appsec1" ref-type="sec">Figures S1 and S2</xref>). All variables were also included in a multivariable logistic regression model in order to analyze the impact of CPD on overall stroke, major stroke, in-hospital mortality, and 30-day readmission rates among patients with AF undergoing TAVR. In the present study, a 2-sided <italic>p</italic> value of &#x0003c;0.05 was considered statistically significant. Data extraction and statistical analyses were performed using SAS (SAS Institute Inc, Cary, North Carolina), SPSS Statistics version 29 (IBM SPSS, Armonk, New York), and RStudio.</p></sec></sec><sec id="sec3"><title>Results</title><sec id="sec3.1"><title>Study Cohort</title><p id="p0085"><xref rid="fig1" ref-type="fig">Figure 1</xref> depicts the patient selection for the present study. Of 271,804 eligible transfemoral TAVR patients, 100,928 (37.1%) patients had an underlying diagnosis of AF and were included in the final analysis. The overall mean (SD) age of patients was 80.4 (7.7) years, with the majority being males (58.5%), being treated at metropolitan teaching hospitals (88.2%) (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>). CPD was used in 6916 (6.9%) of patients with a mean age of 80 years. CPD vs no-CPD patients were more commonly males (62.6% vs. 58.2%), with a lesser burden of comorbidities such as diabetes with chronic complications (14.3% vs. 17.4%), chronic pulmonary disease (24.9% vs. 26.3%), carotid artery disease (5.6% vs. 6.3%), end-stage renal disease on dialysis (2.9% vs. 4.0%), and prior coronary bypass surgery (15.6% vs. 17.7%).<fig id="fig1"><label>Figure&#x000a0;1</label><graphic xlink:href="gr1"/></fig><table-wrap position="float" id="tbl1"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics of TF-TAVR patients with atrial fibrillation</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Characteristics</th><th colspan="4">Unmatched<hr/></th><th colspan="3">PS-matched<hr/></th></tr><tr><th>Overall<break/>N = 100,928</th><th>No CPD<break/>N = 94,012 (93.1%)</th><th>CPD<break/>N = 6916 (6.9%)</th><th><italic>p</italic> value</th><th>No CPD<break/>N = 15,826</th><th>CPD<break/>N = 6916</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Mean age in y (SD)</td><td>80.42 (7.69)</td><td>80.44 (7.69)</td><td>80.19 (7.79)</td><td>0.255</td><td>80.36 (7.63)</td><td>80.19 (7.79)</td><td>0.418</td></tr><tr><td>Females</td><td>41,873 (41.5)</td><td>39,289 (41.8)</td><td>2584 (37.4)</td><td>&#x0003c;0.001</td><td>5974 (37.7)</td><td>2584 (37.4)</td><td>0.581</td></tr><tr><td>Bicuspid aortic valve</td><td>1190 (1.2)</td><td>1032 (1.1)</td><td>158 (2.3)</td><td>&#x0003c;0.001</td><td>358 (2.3)</td><td>158 (2.3)</td><td>0.918</td></tr><tr><td>Prior valve surgery</td><td>5278 (5.2)</td><td>4958 (5.3)</td><td>320 (4.6)</td><td>0.020</td><td>654 (4.1)</td><td>320 (4.6)</td><td>0.090</td></tr><tr><td>Metropolitan teaching hospital</td><td>88,971 (88.2)</td><td>82,467 (87.7)</td><td>6504 (94.0)</td><td>&#x0003c;0.001</td><td>14,933 (34.4)</td><td>6504 (94.0)</td><td>0.348</td></tr><tr><td>Hypertension</td><td>92,376 (91.5)</td><td>86,038 (91.5)</td><td>6338 (91.6)</td><td>0.720</td><td>14,434 (91.2)</td><td>6338 (91.6)</td><td>0.280</td></tr><tr><td>Diabetes without chronic complications</td><td>12,789 (12.7)</td><td>11,868 (12.6)</td><td>921 (13.3)</td><td>0.095</td><td>2141 (13.5)</td><td>921 (13.3)</td><td>0.665</td></tr><tr><td>Diabetes with chronic complications</td><td>17,347 (17.2)</td><td>16,359 (17.4)</td><td>988 (14.3)</td><td>&#x0003c;0.001</td><td>2269 (14.3)</td><td>988 (14.3)</td><td>0.914</td></tr><tr><td>Chronic pulmonary disease</td><td>26,450 (26.2)</td><td>24,731 (26.3)</td><td>1719 (24.9)</td><td>0.008</td><td>3782 (23.9)</td><td>1719 (24.9)</td><td>0.123</td></tr><tr><td>Carotid artery disease</td><td>6344 (6.3)</td><td>5959 (6.3)</td><td>385 (5.6)</td><td>0.011</td><td>783 (4.9)</td><td>385 (5.6)</td><td>0.052</td></tr><tr><td>ESRD on dialysis</td><td>3921 (3.9)</td><td>3721 (4.0)</td><td>200 (2.9)</td><td>&#x0003c;0.001</td><td>439 (2.8)</td><td>200 (2.9)</td><td>0.622</td></tr><tr><td>Prior CABG</td><td>17,699 (17.5)</td><td>16,620 (17.7)</td><td>1079 (15.6)</td><td>&#x0003c;0.001</td><td>2354 (14.9)</td><td>1079 (15.6)</td><td>0.159</td></tr><tr><td>Prior PCI</td><td>21,338 (21.1)</td><td>19,825 (21.1)</td><td>1513 (21.9)</td><td>0.212</td><td>3438 (21.7)</td><td>1513 (21.9)</td><td>0.799</td></tr><tr><td>Prior PPM</td><td>15,422 (15.3)</td><td>14,341 (15.3)</td><td>1081 (15.6)</td><td>0.402</td><td>2322 (14.7)</td><td>1081 (15.6)</td><td>0.062</td></tr><tr><td>Prior CVA</td><td>600 (0.6)</td><td>560 (0.6)</td><td>40 (0.6)</td><td>0.857</td><td>70 (0.4)</td><td>40 (0.6)</td><td>0.174</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p><italic>Notes</italic>. Results presented as N (%) unless otherwise mentioned.</p></fn><fn id="tspara0020"><p>Abbreviations: CABG, coronary artery bypass grafting; CPD, cerebral protection device; CVA, cerebrovascular accident; ESRD, end-stage renal disease; PCI, percutaneous coronary intervention; PPM, pacemaker; PS, propensity score; TAVR, transcatheter aortic valve replacement; TF, transfemoral.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="sec4"><title>Outcomes</title><p id="p0090"><xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref> shows the overall outcomes of patients as well as outcomes of patients stratified by the use of CPD. Around 2.2% of all TAVR patients suffered a stroke in hospital, with 1.8% suffering a major stroke, and 1.5% in-hospital deaths. The median (interquartile range) length of stay for patients was 2 (1-5) days, and 64% of patients were routinely discharged to home. The overall 30-day readmission rate was 14.5% among TAVR patients with AF.<table-wrap position="float" id="tbl2"><label>Table&#x000a0;2</label><caption><p>Outcomes of TF-TAVR patients with atrial fibrillation</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Outcomes</th><th rowspan="2">Overall<break/>N = 100,928</th><th colspan="3">Unmatched<hr/></th><th colspan="3">PS-matched<hr/></th></tr><tr><th>No CPD<break/>N = 94,012 (93.1%)</th><th>CPD<break/>N = 6916 (6.9%)</th><th><italic>p</italic> value</th><th>No CPD<break/>N = 15,826</th><th>CPD<break/>N = 6916</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="8">Outcomes of patients</td></tr><tr><td>Overall stroke</td><td>2183 (2.2)</td><td>2064 (2.2)</td><td>119 (1.7)</td><td>0.009</td><td>344 (2.2)</td><td>119 (1.7)</td><td>0.026</td></tr><tr><td>Major stroke<xref rid="tbl2fnlowast" ref-type="table-fn">&#x02217;</xref></td><td>1803 (1.8)</td><td>1719 (1.8)</td><td>84 (1.2)</td><td>&#x0003c;0.001</td><td>287 (1.8)</td><td>84 (1.2)</td><td>0.001</td></tr><tr><td>Median length of stay in d (IQR)</td><td>2.0 (1-5)</td><td>2.0 (1-5)</td><td>2.0 (1-4)</td><td>&#x0003c;0.001</td><td>2.0 (1-5)</td><td>2 (1-4)</td><td>&#x0003c;0.001</td></tr><tr><td>Routine discharge</td><td>64,806 (64.2)</td><td>60,094 (63.9)</td><td>4712 (68.1)</td><td>&#x0003c;0.001</td><td>10,398 (65.7)</td><td>4712 (68.1)</td><td>&#x0003c;0.001</td></tr><tr><td>In-hospital mortality</td><td>1524 (1.5)</td><td>1465 (1.6)</td><td>59 (0.9)</td><td>&#x0003c;0.001</td><td>243 (1.5)</td><td>59 (0.9)</td><td>&#x0003c;0.001</td></tr><tr><td>30-d readmission rate<xref rid="tbl2fndagger" ref-type="table-fn">&#x02020;</xref></td><td>13,239/91,192 (14.5)</td><td>12,454/85,025 (14.6)</td><td>785/6167 (12.7)</td><td>&#x0003c;0.001</td><td>2101/14,325 (14.7)</td><td>785/6167 (12.7)</td><td>&#x0003c;0.001</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="4">Multivariable logistic regression (CPD vs. no CPD)<hr/></th></tr><tr><th/><th>Odds ratio</th><th>95% CI</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Overall stroke</td><td align="char">0.814</td><td align="char">0.675-0.982</td><td align="char">0.032</td></tr><tr><td>Major stroke<xref rid="tbl2fnlowast" ref-type="table-fn">&#x02217;</xref></td><td align="char">0.691</td><td align="char">0.554-0.862</td><td align="char">0.001</td></tr><tr><td>In-hospital mortality</td><td align="char">0.556</td><td align="char">0.428-0.723</td><td align="char">&#x0003c;0.001</td></tr><tr><td>30-d readmission rate<xref rid="tbl2fndagger" ref-type="table-fn">&#x02020;</xref></td><td align="char">0.873</td><td align="char">0.808-0.943</td><td align="char">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tspara0030"><p><italic>Notes</italic>. Results presented as N (%) unless otherwise mentioned.</p></fn><fn id="tspara0035"><p>Abbreviations: CPD, cerebral protection device; IQR, interquartile range; PS, propensity score; TAVR, transcatheter aortic valve replacement; TF, transfemoral.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnlowast"><label>&#x02217;</label><p id="ntpara0010">Major stroke was defined as stroke leading to death or nonroutine discharge.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fndagger"><label>&#x02020;</label><p id="ntpara0015">30-d readmissions were calculated among patients discharged alive during the first 11 mo of the y to allow for 30-d follow-up.</p></fn></table-wrap-foot></table-wrap></p><p id="p0095">In the unmatched analysis, those who underwent TAVR with vs without CPD had lower overall stroke (1.7% vs. 2.2%; <italic>p</italic> = 0.009), major stroke (1.2% vs. 1.8%; <italic>p</italic> &#x0003c; 0.001), in-hospital mortality (0.9% vs. 1.6%; <italic>p</italic> &#x0003c; 0.001), shorter length of stay (2 [1-4] vs. 2 [1-5] days; <italic>p</italic> &#x0003c; 0.001), higher routine discharges (68.1% vs. 63.9%; <italic>p</italic> &#x0003c; 0.001), and lower 30-day readmission rates (12.7% vs. 14.6%; <italic>p</italic> &#x0003c; 0.001). Similarly, in the propensity score-matched analysis, CPD patients had lower overall stroke (1.7% vs. 2.2%; <italic>p</italic> = 0.026), major stroke (1.2% vs. 1.8%; <italic>p</italic> = 0.001), in-hospital mortality (0.9% vs. 1.5%; <italic>p</italic> &#x0003c; 0.001), shorter length of stay (2 [1-4] vs. 2 [1-5] days; <italic>p</italic> &#x0003c; 0.001), higher routine discharges (68.1% vs. 65.7%; <italic>p</italic> &#x0003c; 0.001), and lesser readmission rates (12.7% vs. 14.7%; <italic>p</italic> &#x0003c; 0.001). The multivariable logistic regression model showed that CPD use was independently associated with lower overall stroke (odds ratio, 0.81 [95% CI 0.68-0.98]; <italic>p</italic> = 0.032), major stroke (0.69 [0.55-0.86]; <italic>p</italic> = 0.001), in-hospital mortality (0.56 [0.43-0.72]; <italic>p</italic> &#x0003c; 0.001), and lower 30-day readmission rates (0.87 [0.81-0.94]; <italic>p</italic> &#x0003c; 0.001.</p><sec id="sec4.1"><title>Outcomes Stratified by Annual Hospital Procedural Volume</title><p id="p0100">Of 100,928 included patients, 36,619 (36.3%) underwent TAVR at low-volume centers (3.1% with CPD; 96.9% without CPD), while 64,309 (63.7%) underwent TAVR at high-volume centers (91.0% without CPD; 9.0% with CPD) (<xref rid="tbl3" ref-type="table">Table&#x000a0;3</xref>). In the low-volume TAVR centers, although CPD patients had higher routine discharges (70.2% vs. 66.9%; <italic>p</italic> = 0.018), there was no significant difference in overall stroke (<italic>p</italic> = 0.078), major stroke (<italic>p</italic> = 0.120), in-hospital mortality (<italic>p</italic> = 0.412), or the 30-day readmission rates (<italic>p</italic> = 0.899). In the high-volume TAVR centers, CPD patients had lower overall stroke (1.8% vs. 2.2%; <italic>p</italic> = 0.032), major stroke (1.2% vs. 1.9%; <italic>p</italic> &#x0003c; 0.001), in-hospital mortality (0.7% vs. 1.5%; <italic>p</italic> &#x0003c; 0.001), shorter length of stay (2 [1-4] vs. 2 [1-5] days; <italic>p</italic> &#x0003c; 0.001), higher routine discharges (67.7% vs. 62.1%; <italic>p</italic> &#x0003c; 0.001), and lesser 30-day readmission rates (12.2% vs. 14.4%; <italic>p</italic> &#x0003c; 0.001).<table-wrap position="float" id="tbl3"><label>Table&#x000a0;3</label><caption><p>Outcomes of TF-TAVR patients with atrial fibrillation stratified by annual hospital procedural volume</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Outcomes</th><th colspan="4">Low-volume TAVR center (&#x02264;99 procedures/y)<hr/></th><th colspan="4">High-volume TAVR center (&#x02265;100 procedures/y)<hr/></th></tr><tr><th>Overall<break/>N = 36,619</th><th>No CPD<break/>N = 35,474</th><th>CPD<break/>N = 1145</th><th><italic>p</italic> value</th><th>Overall<break/>N = 64,309</th><th>No CPD<break/>N = 58,538</th><th>CPD<break/>N = 5771</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Overall stroke</td><td>783 (2.1)</td><td>767 (2.2)</td><td>16 (1.4)</td><td>0.078</td><td>1400 (2.2)</td><td>1297 (2.2)</td><td>103 (1.8)</td><td>0.032</td></tr><tr><td>Major stroke</td><td>631 (1.7)</td><td>618 (1.7)</td><td>13 (1.1)</td><td>0.120</td><td>1172 (1.8)</td><td>1101 (1.9)</td><td>71 (1.2)</td><td>&#x0003c;0.001</td></tr><tr><td>Median length of stay in d (IQR)</td><td>2 (1-4)</td><td>2 (1-4)</td><td>2 (1-4)</td><td>&#x0003c;0.001</td><td>2 (1-5)</td><td>2 (1-5)</td><td>2 (1-4)</td><td>&#x0003c;0.001</td></tr><tr><td>Routine discharge</td><td>24,533 (67.0)</td><td>23,729 (66.9)</td><td>804 (70.2)</td><td>0.018</td><td>40,273 (62.6)</td><td>36,365 (62.1)</td><td>3908 (67.7)</td><td>&#x0003c;0.001</td></tr><tr><td>In-hospital mortality</td><td>625 (1.7)</td><td>609 (1.7)</td><td>16 (1.4)</td><td>0.412</td><td>899 (1.4)</td><td>856 (1.5)</td><td>43 (0.7)</td><td>&#x0003c;0.001</td></tr><tr><td>30-d readmissions</td><td>4949/32,879 (15.1)</td><td>4796/31,872 (15.0)</td><td>153/1007 (15.2)</td><td>0.899</td><td>8290/58,313 (14.2)</td><td>7658/53,153 (14.4)</td><td>632/5160 (12.2)</td><td>&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tspara0045"><p><italic>Notes</italic>. Unweighted numbers were used for the calculation and reporting of outcomes by annual hospital procedural volume.</p></fn><fn id="tspara0050"><p>Abbreviations: CPD, cerebral protection device; IQR, interquartile range; TAVR, transcatheter aortic valve replacement; TF, transfemoral.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="sec5"><title>Discussion</title><p id="p0105">In the present study from a nationally representative all-comers database, we found that CPD use among patients with AF undergoing TAVR was associated with lower rates of overall stroke, major stroke, in-hospital mortality, and consequently shorter duration of hospital stay, more frequent routine discharges, and lower-30-day readmission rates. Furthermore, CPD use in high-volume TAVR centers showed beneficial effects in reducing adverse events, although this reduction in adverse events was not noticed among patients undergoing TAVR at low-volume TAVR centers.</p><p id="p0110">During valve deployment, calcium deposits get dislodged into the carotid or the vertebral arteries leading to stroke. The Sentinel CPD consists of 2 filters, one which is threaded into the right radial artery, and the second which is deployed to the carotid artery, with a logical aim to capture the dislodged debris. The CPD protects only &#x0223c;80% of cerebral circulation, which is perhaps why the largest CPD RCT, PROTECTED TAVR, suggested benefits of CPD use in preventing disabling stroke, but not overall stroke.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> Limited studies have been performed to examine the effects of the CPD device among select patients. In a study from the National Inpatient sample, Zhang et&#x000a0;al. reported lower overall stroke risk as well as lower composite safety endpoint of in-hospital death and stroke with CPD among patients with bicuspid aortic valve undergoing TAVR.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Recently, our group examined the effects of CPD in TAVR patients with a failed bioprosthesis and found that CPD use was associated with lower adverse events including major stroke in this important patient population.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> With the Sentinel device being in its seventh year of use after the United States Food and Drug Administration approval in 2017, there is an interest in recognizing high stroke-risk patients who may potentially benefit from CPD use, given the lack of conclusive RCT data depicting risk reduction among all-comers.</p><p id="p0115">Patient- and procedure-related factors such as prior history of stroke, AF, severe calcification, prolonged procedure time, rapid pacing, and extensive aortic manipulation have been previously described as predictors of stroke following TAVR.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Studies have shown potential benefits of CPD use in high-risk patients.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> A recent meta-analysis of 6 RCTs reported that the Sentinel CPD was safe and reduced disabling stroke during the TAVR procedure in select patients at high to intermediate surgical risk.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> A reduction in imaging markers for stroke after TAVR has been reported in prior analyses of RCTs.<xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref> Patients with AF are considered high-risk, with more advanced cardiovascular disease. Studies have shown AF to be an independent predictor of worse outcomes in patients with AS.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref><sup>,</sup><xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> In a study including 1847 patients with severe AS, presence of AF was shown to be associated with poor prognosis.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> Furthermore, prior literature has shown AF to be a major predictor of mortality in patients with AS.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> In a global, patient-level analysis, Vlastra et&#x000a0;al.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> reported a 5-fold higher rate of AF in TAVR patients who developed stroke. In this regard, we found that CPD was associated with lower overall stroke, major stroke, in-hospital mortality, and 30-day readmissions among patients with AF undergoing TAVR.</p><p id="p0120">We also found that CPD when used in low-volume TAVR centers was not associated with a reduction in adverse events, including 30-day mortality. On the other hand, high-volume TAVR centers showed a significant reduction in overall stroke rate, major stroke rate, mortality rate, along with a shorter length of hospital stay, and more frequent routine discharges and lower 30-day readmission rate when the CPD device was used. A study from the 2018 NRD showed an inverse relation between increasing CPD volume use and in-hospital stroke.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> This highlights that operator experience likely plays an important role in the appropriate utilization of the CPD device, and the subsequently observed reduced adverse events. However, there could be other procedural factors such as, access site, predilation and postdilation, valve types, height of implantation, anesthesia, and others, which may also affect these observed changes.<xref rid="bib22" ref-type="bibr">22</xref>, <xref rid="bib23" ref-type="bibr">23</xref>, <xref rid="bib24" ref-type="bibr">24</xref></p><sec id="sec5.1"><title>Study Limitations</title><p id="p0125">The present retrospective study is inherently limited by the use of an administrative database which relies on codes for capturing diagnoses and procedures. Although we adjusted for all patient characteristics to look at the association of CPD with adverse events, association does not necessarily imply causation, and results may still be driven by other unadjusted or adjusted confounders. The data source also lacks important data on surgical risk scores and neurological assessment of stroke. Procedural details such as predilation and postdilation, use of anticoagulation, medication details, anesthesia, valve types, and others are not obtainable from the data source used for the present study.</p></sec></sec><sec id="sec6"><title>Conclusion</title><p id="p0130">The present study from an all-comers nationally representative database points toward clear benefits of CPD use among patients with AF undergoing TAVR. In anatomically eligible patients, the potential benefit of debris capture may be considered especially as younger and lower risk patients become eligible for TAVR.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> Data from future trials and registries are required to further corroborate our findings.</p></sec><sec id="sec7"><title>Ethics Statement</title><p id="p0180">The data utilized for the present study is derived from a publicly available database containing deidentified information. Approval from the Institutional Review Board was not required for the study.</p></sec><sec id="sec8"><title>Funding</title><p id="p0140">This study was made possible by a generous gift from Jennifer and Robert McNeil. The funders had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Disclosure Statement</title><p id="p0135">The authors report no conflict of interest.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Stachon</surname><given-names>P.</given-names></name><name><surname>Kaier</surname><given-names>K.</given-names></name><name><surname>Zirlik</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Risk-adjusted comparison of in-hospital outcomes of transcatheter and surgical aortic valve replacement</article-title><source>J&#x000a0;Am Heart Assoc</source><volume>8</volume><year>2019</year><object-id pub-id-type="publisher-id">e011504</object-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Mack</surname><given-names>M.J.</given-names></name><name><surname>Leon</surname><given-names>M.B.</given-names></name><name><surname>Thourani</surname><given-names>V.H.</given-names></name><etal/></person-group><article-title>Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients</article-title><source>N&#x000a0;Engl J Med</source><volume>380</volume><year>2019</year><fpage>1695</fpage><lpage>1705</lpage><pub-id pub-id-type="pmid">30883058</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Kapadia</surname><given-names>S.</given-names></name><name><surname>Agarwal</surname><given-names>S.</given-names></name><name><surname>Miller</surname><given-names>D.C.</given-names></name><etal/></person-group><article-title>Insights into timing, risk factors, and outcomes of stroke and transient ischemic attack after transcatheter aortic valve replacement in the partner trial (placement of aortic transcatheter valves)</article-title><source>Circ Cardiovascular Interventions</source><volume>9</volume><issue>9</issue><year>2016</year><object-id pub-id-type="publisher-id">e002981</object-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Kleiman</surname><given-names>N.S.</given-names></name><name><surname>Maini</surname><given-names>B.J.</given-names></name><name><surname>Reardon</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Neurological events following transcatheter aortic valve replacement and their predictors: a report from the corevalve trials</article-title><source>Circ Cardiovasc Interv</source><volume>9</volume><year>2016</year><object-id pub-id-type="publisher-id">e00351</object-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Jimenez Diaz</surname><given-names>V.A.</given-names></name><name><surname>Kapadia</surname><given-names>S.R.</given-names></name><name><surname>Linke</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Cerebral embolic protection during transcatheter heart interventions</article-title><source>EuroIntervention</source><volume>19</volume><year>2023</year><fpage>549</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">37720969</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Kapadia</surname><given-names>S.R.</given-names></name><name><surname>Makkar</surname><given-names>R.</given-names></name><name><surname>Leon</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Cerebral embolic protection during transcatheter aortic-valve replacement</article-title><source>N&#x000a0;Engl J Med</source><volume>387</volume><year>2022</year><fpage>1253</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">36121045</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Kapadia</surname><given-names>S.R.</given-names></name><name><surname>Kodali</surname><given-names>S.</given-names></name><name><surname>Makkar</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Protection against cerebral embolism during transcatheter aortic valve replacement</article-title><source>J&#x000a0;Am Col Cardiol (JACC)</source><volume>69</volume><year>2017</year><fpage>367</fpage><lpage>377</lpage></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Kapadia</surname><given-names>S.R.</given-names></name></person-group><article-title>Routine use of embolic protection during transcatheter aortic valve replacement</article-title><source>JACC Cardiovasc Interv</source><volume>10</volume><year>2017</year><fpage>2304</fpage><lpage>2306</lpage><pub-id pub-id-type="pmid">28917514</pub-id>
</element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="other" id="sref9"><person-group person-group-type="author"><collab>Healthcare cost and utilization project (hcup)</collab></person-group><article-title>Nrd Overview</article-title><ext-link ext-link-type="uri" xlink:href="https://www.Hcup-us.Ahrq.Gov/nrdoverview.Jsp" id="intref0015">https://www.Hcup-us.Ahrq.Gov/nrdoverview.Jsp</ext-link></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>von Elm</surname><given-names>E.</given-names></name><name><surname>Altman</surname><given-names>D.G.</given-names></name><name><surname>Egger</surname><given-names>M.</given-names></name><name><surname>Pocock</surname><given-names>S.J.</given-names></name><name><surname>G&#x000f8;tzsche</surname><given-names>P.C.</given-names></name><name><surname>Vandenbroucke</surname><given-names>J.P.</given-names></name></person-group><article-title>The strengthening the reporting of observational studies in epidemiology (strobe) statement: Guidelines for reporting observational studies</article-title><source>J&#x000a0;Clin Epidemiol</source><volume>61</volume><year>2008</year><fpage>344</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">18313558</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Tian</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Outcomes of cerebral embolic protection for bicuspid aortic valve stenosis undergoing transcatheter aortic valve replacement</article-title><source>J&#x000a0;Am Heart Assoc</source><volume>12</volume><year>2023</year><object-id pub-id-type="publisher-id">e028890</object-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Shekhar</surname><given-names>S.</given-names></name><name><surname>Krishnaswamy</surname><given-names>A.</given-names></name><name><surname>Reed</surname><given-names>G.</given-names></name><name><surname>Puri</surname><given-names>R.</given-names></name><name><surname>Yun</surname><given-names>J.</given-names></name><name><surname>Kapadia</surname><given-names>S.</given-names></name></person-group><article-title>Cerebral embolic protection in valve-in-valve transcatheter aortic valve replacement</article-title><source>Am J Cardiol</source><volume>216</volume><year>2024</year><fpage>110</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">38402923</pub-id>
</element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>S.U.</given-names></name><name><surname>Zahid</surname><given-names>S.</given-names></name><name><surname>Alkhouli</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>An updated meta-analysis on cerebral embolic protection in patients undergoing transcatheter aortic valve intervention stratified by baseline surgical risk and device type</article-title><source>Struct Heart</source><volume>7</volume><year>2023</year><object-id pub-id-type="publisher-id">100178</object-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Giustino</surname><given-names>G.</given-names></name><name><surname>Mehran</surname><given-names>R.</given-names></name><name><surname>Veltkamp</surname><given-names>R.</given-names></name><name><surname>Faggioni</surname><given-names>M.</given-names></name><name><surname>Baber</surname><given-names>U.</given-names></name><name><surname>Dangas</surname><given-names>G.D.</given-names></name></person-group><article-title>Neurological outcomes with embolic protection devices in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis of randomized controlled trials</article-title><source>JACC Cardiovasc Interv</source><volume>9</volume><year>2016</year><fpage>2124</fpage><lpage>2133</lpage><pub-id pub-id-type="pmid">27765306</pub-id>
</element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Lansky</surname><given-names>A.</given-names></name><name><surname>Pietras</surname><given-names>C.</given-names></name><name><surname>Shah</surname><given-names>T.</given-names></name></person-group><article-title>Cerebral embolic protection: burden of proof</article-title><source>JACC Cardiovasc Interv</source><volume>13</volume><year>2020</year><fpage>2156</fpage><lpage>2158</lpage><pub-id pub-id-type="pmid">32972579</pub-id>
</element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Latib</surname><given-names>A.</given-names></name><name><surname>Pagnesi</surname><given-names>M.</given-names></name></person-group><article-title>Cerebral embolic protection during transcatheter aortic valve replacement: a disconnect between logic and data?</article-title><source>J&#x000a0;Am Coll Cardiol</source><volume>69</volume><year>2017</year><fpage>378</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">27815102</pub-id>
</element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Moretti</surname><given-names>M.</given-names></name><name><surname>Fabris</surname><given-names>E.</given-names></name><name><surname>Morosin</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Prognostic significance of atrial fibrillation and severity of symptoms of heart failure in patients with low gradient aortic stenosis and preserved left ventricular ejection fraction</article-title><source>Am J Cardiol</source><volume>114</volume><year>2014</year><fpage>1722</fpage><lpage>1728</lpage><pub-id pub-id-type="pmid">25316349</pub-id>
</element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Shekhar</surname><given-names>S.</given-names></name><name><surname>Saad</surname><given-names>A.</given-names></name><name><surname>Isogai</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Impact of atrial fibrillation in aortic stenosis (from the United States readmissions database)</article-title><source>Am J Cardiol</source><volume>140</volume><year>2021</year><fpage>154</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">33227240</pub-id>
</element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>El-Am</surname><given-names>E.A.</given-names></name><name><surname>Thaden</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Atrial fibrillation is not an independent predictor of outcome in patients with aortic stenosis</article-title><source>Heart</source><volume>106</volume><year>2020</year><fpage>280</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">31439661</pub-id>
</element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Vlastra</surname><given-names>W.</given-names></name><name><surname>Jimenez-Quevedo</surname><given-names>P.</given-names></name><name><surname>Tch&#x000e9;tch&#x000e9;</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Predictors, incidence, and outcomes of patients undergoing transfemoral transcatheter aortic valve implantation complicated by stroke</article-title><source>Circ Cardiovasc Interv</source><volume>12</volume><year>2019</year><object-id pub-id-type="publisher-id">e007546</object-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Bansal</surname><given-names>A.</given-names></name><name><surname>Isogai</surname><given-names>T.</given-names></name><name><surname>Gad</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>Impact of hospital volume on utilization and outcomes of sentinel cerebral protection system during transcatheter aortic valve implantation</article-title><source>Am J Cardiol</source><volume>178</volume><year>2022</year><fpage>171</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">35842278</pub-id>
</element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Ternacle</surname><given-names>J.</given-names></name><name><surname>Al-Azizi</surname><given-names>K.</given-names></name><name><surname>Szerlip</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Impact of predilation during transcatheter aortic valve replacement: Insights from the partner 3 trial</article-title><source>Circ Cardiovasc Interv</source><volume>14</volume><year>2021</year><object-id pub-id-type="publisher-id">e010336</object-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Butala</surname><given-names>N.M.</given-names></name><name><surname>Chung</surname><given-names>M.</given-names></name><name><surname>Secemsky</surname><given-names>E.A.</given-names></name><etal/></person-group><article-title>Conscious sedation versus general anesthesia for transcatheter aortic valve replacement: Variation in practice and outcomes</article-title><source>JACC Cardiovasc Interv</source><volume>13</volume><year>2020</year><fpage>1277</fpage><lpage>1287</lpage><pub-id pub-id-type="pmid">32499018</pub-id>
</element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Sammour</surname><given-names>Y.</given-names></name><name><surname>Banerjee</surname><given-names>K.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Systematic approach to high implantation of sapien-3 valve achieves a lower rate of conduction abnormalities including pacemaker implantation</article-title><source>Circ Cardiovasc Interv</source><volume>14</volume><year>2021</year><object-id pub-id-type="publisher-id">e009407</object-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Kawakami</surname><given-names>R.</given-names></name><name><surname>Gada</surname><given-names>H.</given-names></name><name><surname>Rinaldi</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Characterization of cerebral embolic capture using the sentinel device during transcatheter aortic valve implantation in low to intermediate-risk patients: the sentinel-lir study</article-title><source>Circ Cardiovasc Interv</source><volume>15</volume><year>2022</year><object-id pub-id-type="publisher-id">e011358</object-id></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supplementary Material</title><p id="p0145">
<supplementary-material content-type="local-data" id="mmc1"><caption><title>Supplementary Table and Figure</title></caption><media xlink:href="mmc1.docx"/></supplementary-material>
</p></sec><fn-group><fn id="appsec2" fn-type="supplementary-material"><p id="p0150">Supplemental data for this article can be accessed on the <ext-link ext-link-type="doi" xlink:href="10.1016/j.shj.2024.100353" id="intref0010">publisher&#x02019;s website</ext-link>.</p></fn></fn-group></back></article>